Clinical data and radiological severity score (RAD-Covid Score) of chest CT scans from COVID-19 patients.

NOTE: there is no peer-reviewed publication associated with this data record.<br>This fileset consists of three datasets in <b>.xlsx</b> file format.<br>Dataset <b>CLIN LAB DATA RAD-Covid (1).xlsx </b>contains the patients’ demographic data, comorbidities, and outcome (death or recovery), collected from the institution’s electronic medical records. Additionally, the file contains clinical severity of COVID-19, upon hospital admission. This was classified according to the institution’s treatment protocol for patients with suspected Covid-19: mild (home treatment), moderate (hospitalization), or severe (intensive care unit [ICU] admission).<br>Dataset <b>consensus RADIOLOGISTS CT AVAL. PATTERNS AND DISTRIBUTION OF LESIONS (1).xlsx</b> contains the chest CT imaging findings (i.e the radiological patterns and distribution of lesions).<br>Dataset <b>RAD-COVID SCORE AGREEMENT (1).xlsx </b>contains the radiological severity score (RAD-Covid Score) that was assigned to the CT scan of each patient.The scores were assigned by two radiologists, at independent workstations, and the results are shown in spreadsheets “Radiologist 1” and “Radiologist 2”, respectively. The percentage values next to each RAD-Covid Score represent pulmonary involvement.<br><b>Study aims and methodology: </b>The severity of pulmonary Covid-19 infection can be assessed by the pattern and extent of parenchymal involvement observed in computed tomography (CT), and it is important to standardize the analysis through objective, practical, and reproducible systems.In this study, the authors propose a method for stratifying the radiological severity of pulmonary disease, the Radiological Severity Score (RAD-Covid Score), in Covid-19 patients by quantifying infiltrate in chest CT, including assessment of its accuracy in predicting disease severity.The study was approved by the institutional research ethics committee, although the consent requirement was waived due to its retrospective nature.Institutional Review Board approval was obtained from Dante Pazzanese Cardiology Institute Ethical Committee CAAE: 32408920.2.0000.5462.A total of 658 patients were included in the study. Only patients (a) whose Covid-19 infection was confirmed by real-time polymerase chain reaction and (b) who underwent chest CT on admission between March 6 and April 6, 2020 were included. Patients (a) whose real-time polymerase chain reaction examinations were performed more than 7 days after chest CT and (b) who were under 18 years of age were excluded.The patients’ demographic data (age, gender), comorbidities, and outcome (death or recovery) were collected from the institution’s electronic medical records. Clinical severity upon hospital admission was classified according to the institution’s treatment protocol for patients with suspected Covid-19: mild (home treatment), moderate (hospitalization), or severe (intensive care unit [ICU] admission).Chest CT scans were obtained through low-radiation-dose on a 160-MDCT (Aquilion Prime CT, Toshiba/Canon), 64-MDCT (Optma 660, GE), 16-MDCT (Somaton Scope,Siemens), 16-MDCT (Alexion, Toshiba/Canon) and 16-MDCT (BrightSpeed, GE Heathcare). Two radiologists, both with 8 years’ experience in chest imaging and blinded to the clinical and laboratory data, performed a standardized review of all chest CT images at independent workstations.For more details on the methodology and statistical analysis, please read the related article.<br>